证券代码：301047 证券简称：义翘神州 公告编号：2025-037 一、董事会会议召开情况 北京义翘神州科技股份有限公司（以下简称"公司"）第二届董事会第十八 次会议通知于 2025 年 11 月 13 日以通讯方式送达全体董事，会议于 2025 年 11 月 18 日在公司会议室以现场和通讯方式召开。本次会议应出席董事 7 人，实际 出席董事 7 人，公司部分监事及高级管理人员列席了本次会议。本次会议由董事 长谢良志博士召集并主持，本次会议的召集和召开程序符合《公司法》等法律法 规、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： 1、逐项审议通过《关于董事会换届选举暨提名第三届董事会非独立董事候 选人的议案》 公司第二届董事会将于 2026 年 3 月 22 日届满，根据《公司法》等法律法规、 规范性文件以及《公司章程》的有关规定，并结合公司实际情况，公司决定提前 开展董事会换届选举工作。经公司董事会提名与薪酬委员会资格审核，董事会提 名谢良志先生、张杰先生、冯涛先生为公司第三届董事会非独立董事候选人，任 期自股东大会审议通过之日 ...

每经AI快讯，义翘神州（SZ 301047，收盘价：73.45元）11月18日晚间发布公告称，公司第二届第十八 次董事会会议于2025年11月18日在公司会议室以现场和通讯方式召开。会议审议了《关于修订 <公司章 程> 的议案》等文件。 2024年1至12月份，义翘神州的营业收入构成为：研究和试验发展占比95.7%，房屋租赁占比4.3%。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 曾健辉） 截至发稿，义翘神州市值为89亿元。 ...

Core Viewpoint - The article discusses the seasonal influenza epidemic and the interactions between various respiratory viruses, highlighting the importance of understanding viral co-infections and their implications for public health and treatment strategies [2][3]. Summary by Sections Influenza Season and Predictions - The seasonal influenza typically peaks in China between mid-December and early January, with an expected rise in cases this year [2]. Viral Co-infections and Their Effects - Respiratory viruses such as influenza, respiratory syncytial virus (RSV), rhinovirus, and others can co-infect hosts, leading to varying clinical outcomes, either exacerbating or alleviating symptoms [3][4]. - Co-infections can result in two distinct outcomes: either reducing symptoms or worsening them, as demonstrated in mouse models [4][6]. Mechanisms of Viral Interference - Viral interference can be classified into positive and negative interactions. Positive interactions can worsen conditions, while negative interactions can inhibit viral infections [3][5]. - The concept of viral interference was introduced in the 1960s, with interferon responses being a key mechanism in these interactions [5][10]. Implications for Treatment and Research - Understanding the mechanisms of viral interference is crucial for developing treatment, prevention, and diagnostic strategies for infectious diseases [10]. - The article emphasizes the role of viral surface proteins in these interactions, suggesting that recombinant viral antigens and antibodies are essential for research [10]. Company Solutions - Yiqiao Shenzhou provides a comprehensive range of viral reagents and solutions for infectious disease research, supporting global efforts in basic research, therapeutic antibody development, drug research, diagnostics, and vaccine development [12][13].

Core Insights - The ADAR (Adenosine deaminases acting on RNA) family plays a crucial role in RNA editing, immune homeostasis, and neurological functions, with significant advancements in ADAR-mediated RNA editing technology in recent years [2] - Unlike CRISPR-based editing, ADAR-based RNA editing requires only the expression of endogenous deaminase ADAR in cells, avoiding delivery challenges and related immunogenicity issues, thus providing a safer option for precise RNA editing without altering genomic sequences [2] - ADAR-mediated RNA editing shows great potential in treating genetic diseases and cancers, with clinical trials approved for therapies targeting conditions like α-1 antitrypsin deficiency (AATD) and Stargardt disease, as well as inhibiting tumor growth by precisely editing oncogenic mRNA [2] Group 1: ADAR Family and RNA Editing - The ADAR family is essential for catalyzing RNA A-to-I editing, which regulates RNA diversity and maintains immune and neurological functions [2] - ADAR-mediated RNA editing technology has rapidly developed, distinguishing itself from CRISPR-based methods by its safety and precision [2] Group 2: ADAR1 as a Drug Target - ADAR1 is closely associated with various diseases, including type I interferonopathies, cancers, and viral infections, making it an important drug target [3] - Development strategies for ADAR1 inhibitors include targeting its catalytic domain, regulating upstream and downstream signaling pathways, and employing PROTAC degradation technology, showing promise in cancer and autoimmune disease treatments [3] Group 3: Upcoming Webinar - A webinar titled "Decoding ADAR: From RNA Editing, Innovative Inhibitor Development Strategies to SignalChem Screening Services" is scheduled for November 20, featuring experts from the industry [4][8] - Judy Zhu, a senior product manager, will discuss the role of ADAR-mediated RNA editing in cancer treatment and the significance of ADAR1 as a drug target [3][10] - Eric Yao, a senior scientist, will present on the development and screening strategies for ADAR1-targeted inhibitors, highlighting SignalChem's services in supporting research and drug development [3][9]

Group 1 - The core viewpoint of the article highlights that Yiqiao Shenzhou (SZ 301047) will hold an investor meeting on November 3, 2025, with participation from key executives including the general manager and R&D director [1] - For the year 2024, Yiqiao Shenzhou's revenue composition is reported to be 95.7% from research and experimental development and 4.3% from property leasing [1] - As of the report, Yiqiao Shenzhou has a market capitalization of 9.3 billion yuan [1] Group 2 - The article mentions a significant increase in overseas orders for a certain industry, with a reported growth of 246%, covering over 50 countries and regions [1] - Entrepreneurs are warned about the risk of cutthroat competition as some are selling at a loss, which could extend to international markets [1]

Core Viewpoint - The company, Yiqiao Shenzhou Technology Co., Ltd., reported strong financial performance for Q3 2025, with significant growth in both revenue and net profit, driven by domestic and international business expansion [3][4]. Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 186.99 million yuan, representing a year-on-year increase of 17.39% [3] - The net profit for the same period reached 110.18 million yuan, up by 10.94% year-on-year [3] - In Q3 alone, the net profit was 42.49 million yuan, showing a remarkable growth rate of 49.76% compared to the previous year [3] Group 2: Business Development - The company is experiencing stable growth in both domestic and international markets, with a focus on expanding its market share and brand recognition in China while enhancing its overseas presence [4] - The domestic market has shown strong demand, while the overseas market, although in its early stages, presents significant growth potential due to competitive product pricing [4] Group 3: Product Strategy - The company is implementing a dual-track strategy for cytokine products, balancing GMP and non-GMP offerings to cater to different customer needs [5] - The SCB business segment has shown steady revenue growth, with initial signs of successful integration and collaboration between the company's existing capabilities and the SCB products [6] - The company currently offers over 9,800 types of protein products, positioning itself as a global leader, with plans to enhance product quality and expand antibody offerings through innovation [7]

Financial Performance - In the first three quarters of 2025, the company's revenue reached 51,144.50 million yuan, a year-on-year increase of 10.00% [3] - In Q3 2025, the company achieved revenue of 18,698.98 million yuan, reflecting a year-on-year growth of 17.39% [3] - The net profit for the first three quarters was 11,017.95 million yuan, up 10.94% year-on-year; in Q3, net profit was 4,249.32 million yuan, showing a significant increase of 49.76% [3] Market Development - Domestic business has shown stable growth due to increased industry demand and market expansion, with a solid market share and brand recognition [4] - The overseas market, while still developing, presents significant growth potential due to competitive product pricing and planned marketing efforts to enhance brand awareness [4] Product Development - The company offers two categories of cytokine products: non-GMP for research purposes and GMP-certified for industrial use, with a balanced strategy to expand GMP product offerings [5] - The company has a leading position with over 9,800 types of protein products, focusing on quality upgrades to enhance customer satisfaction [6] - There is an ongoing effort to increase the number of antibody products through continuous R&D innovation [6] Collaboration and Synergy - The collaboration with SCB has resulted in steady revenue growth, with initial integration of product lines enhancing market coverage, particularly in North America [6]

Core Insights - The recombinant protein industry in China, despite its late start, has rapidly developed due to continuous support from national industrial policies, leading to significant breakthroughs in technology, production processes, and quality control [1][15] - The market for recombinant proteins is expected to grow steadily, driven by increased investment in innovative drug research, rising demand for precision medicine, and the expansion of downstream application scenarios [1][15] Industry Overview - Recombinant proteins are proteins obtained through genetic engineering and cell engineering, essential for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents [4] - The industry has experienced three stages: the initial stage (1970-1990), rapid development (1990-2000), and transformation and upgrading (2000-present) [8][9] Market Growth - The market size of China's recombinant protein industry is projected to grow from 5.1 billion yuan in 2015 to 27 billion yuan in 2024, with a compound annual growth rate (CAGR) of 20.34% [1][15] - The global recombinant protein market is expected to increase from $7 billion in 2015 to $18.5 billion in 2024, with a CAGR of 11.4% [13][14] Policy Support - The Chinese government has implemented various policies to encourage technological innovation and market expansion in the biopharmaceutical sector, including funding support for research and expedited drug approval processes [9][10] Industry Chain - The upstream of the recombinant protein industry includes raw materials and equipment, while the midstream consists of recombinant protein products, and the downstream includes customers such as research institutions and pharmaceutical companies [10] Competitive Landscape - The recombinant protein market is characterized by a diverse and dynamic competitive landscape, with major multinational pharmaceutical companies like Pfizer, Roche, and Novartis leading the market, while numerous small and medium-sized enterprises focus on innovative technologies [16][17] Development Trends - The industry is moving towards high-end products, focusing on complex structures and high-value proteins, with an emphasis on product activity, purity, and consistency [18] - Intelligent technologies, including AI and machine learning, are expected to enhance research and production processes, improving efficiency and product quality [19][20] - Chinese recombinant protein companies are increasingly participating in global competition, aiming to meet international standards and establish a strong global presence [21]

Core Viewpoint - Yiqiao Shenzhou (301047.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in fund holdings [1][2] Institutional Ownership - As of October 27, 2025, a total of 10 institutional investors disclosed holdings in Yiqiao Shenzhou A-shares, with a combined holding of 75.024 million shares, representing 61.68% of the total share capital [1] - The top ten institutional investors include various management consulting partnerships and investment firms, with their combined holding percentage decreasing by 0.74 percentage points compared to the previous quarter [1] Public Fund Holdings - In this reporting period, 46 public funds were not disclosed compared to the previous quarter, including notable funds such as Dachen Rui Xiang Mixed A and Southern CSI 1000 ETF [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.16% compared to the previous period [2]

Core Insights - The company reported a revenue of 511 million yuan for the first three quarters of 2025, representing a year-on-year growth of 10.00% [1] - The net profit attributable to shareholders of the listed company was 110 million yuan, with a year-on-year increase of 10.94% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 62.25 million yuan, showing a significant year-on-year growth of 75.30% [1] - The basic earnings per share were 0.9058 yuan [1]